Loading stock data…
4503.T
TSE¥2,321-4.00 (-0.17%)
Market OpenUpdated 9:39 PM EDT
Astellas Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Astellas Pharma Inc. in the Healthcare sector is trading at ¥2,321. The stock is currently 15% below its 52-week high of ¥2,717, remaining 17.1% above its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why 4503.T maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price¥2,321
Potential Downside
38.4%
Whystock Fair Value¥1,431
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target¥2,396+3.2%
Range¥1,600 – ¥2,950
Fundamentals
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥4.44T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
35.63
Beta
Defensive asset. Lower volatility than the S&P 500.
0.15
Div Yield
Strong income play. Yield provides a meaningful total return floor.
312.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.82%
Volume
Today's trading volume
1.25M
Recent News
Assessing Astellas Pharma (TSE:4503) Valuation After A Sharp Pullback And Strong One Year Return
Astellas Pharma (TSE:4503) has been drawing attention after a mixed set of signals, with a 1 day return of 1.12% contrasted against a roughly 17% decline over the past month. See our latest analysis for Astellas Pharma. Despite the recent 7 day share price return of 10.58% decline and a 30 day share price return of 16.95% decline, the current ¥2,207.0 share price sits against a 1 year total shareholder return of 57.40%. This suggests that recent momentum has faded following a stronger run...
Pfizer (PFE) Among Best Medical Stocks Under $30 to Invest In?
Pfizer Inc. (NYSE:PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, together with Astellas Pharma Inc., that the US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Priority Review. The application is for the use of PADCEV (enfortumab vedotin-ejfv) […]
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Merck Says FDA Grants Priority Review to Keytruda-Padcev Combo for Bladder Cancer
Merck (MRK) said Monday that the US Food and Drug Administration (FDA) has granted priority review t
A Look At Astellas Pharma’s Valuation After A Strong Year Of Share Price Gains
What Astellas Pharma’s recent performance tells you now Astellas Pharma (TSE:4503) has drawn investor attention after a period in which the share price delivered double digit total returns over the past year, while reported annual revenue and net income declined. See our latest analysis for Astellas Pharma. Recent trading has been trending upward, with a 30 day share price return of 5.79% and a 90 day share price return of 16.81%. The 1 year total shareholder return of 113.99% points to...